Brent Saunders (Richard Drew, AP Images)
June 24, 2020 08:54 AM EDTUpdated 10:04 AM
People
Bioregnum
Opinion

Day one: The dis­rup­tor-in-chief at Bridge­Bio in­vites Brent Saun­ders on­to the board

Now that Al­ler­gan has been swept up in­to Ab­b­Vie fol­low­ing their $63 bil­lion buy­out, it’s time for ex-CEO Brent Saun­ders to kick­start the …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times